Psoriatic arthritis: current therapy and future approaches

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Psoriatic arthritis (PsA) affects 20-30% of psoriasis patients, involving joints, entheses, and skin.
• PsA presents significant clinical heterogeneity in domain involvement, severity, and activity, complicating treatment.
• While sharing some similarities with rheumatoid arthritis (RA), distinct immunopathophysiology and treatment responses are increasingly recognized.

Purpose of the Study:

• To review current disease-modifying antirheumatic drugs (DMARDs) and biologic agents for PsA.
• To explore the potential role of emerging therapeutics in managing PsA.
• To highlight the distinctions between PsA and RA in terms of immunopathophysiology and targeted therapy response.

Main Methods:

• Literature review of current DMARDs and biologic agents.
• Analysis of recent data on targeted therapies for PsA and RA.
• Exploration of emerging therapeutic strategies for PsA.

Main Results:

• PsA exhibits diverse tissue involvement and variable disease progression.
• Treatment challenges arise from clinical heterogeneity and varying severity.
• Distinct immunopathophysiological features differentiate PsA from RA, influencing therapeutic responses.

Conclusions:

• Current DMARDs and biologics offer treatment options for PsA.
• Emerging therapies hold promise for improved PsA management.
• Understanding PsA-specific mechanisms is crucial for optimizing treatment strategies.